Made Scientific Selected for Columbia’s NOVAKnee Program
PRINCETON, N.J., June 1, 2026 Made Scientific has been selected as the manufacturing partner for Columbia University’s NOVAKnee program,...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PRINCETON, N.J., June 1, 2026 Made Scientific has been selected as the manufacturing partner for Columbia University’s NOVAKnee program,...
Paris, France, April 7, 2026 Phase 2 Success Across Respiratory Indications In a major advancement for respiratory disease therapeutics,...
Boulder, Colorado, USA, April 6, 2026 $33.5M ARPA-H Funding Accelerates Regenerative Pipeline In a major boost to regenerative medicine...
